Hepatocellular Carcinoma
Conditions
Interventions
Experimental group:Irreversible electroporation for ablation treatment of liver cancer
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1. Patients must be able to understand the research protocol and voluntarily follow the protocol for treatment; 2. Patients must be aged between 18 and 75 years; 3. Based on a history of partial liver resection for primary liver cancer and recurrent liver cancer; 4. Confirmed diagnosis of hepatocellular carcinoma through histological or cytological examination, or diagnosed as liver cancer according to the diagnostic criteria of the American Association for the Study of Liver Diseases (AASLD) or the primary liver cancer treatment guidelines, with multiple tumors (number of tumors = 90g/L, white blood cell count >= 3.0×10^9/L, neutrophil count >= 1.5×10^9/L, platelet count >= 50×10^9/L; no clear cachexia manifestations;
Exclusion criteria
Exclusion criteria: Exclusion criteria: 1. History of surgical treatment for other diseases within 4 weeks prior to enrollment; 2. History of spontaneous tumor rupture; 3. Severe infectious diseases, such as bacteremia or toxemia; 4. Irreversible coagulation dysfunction (platelet count 480 ms (calculated using Fridericia method), left ventricular ejection fraction 150 mmHg and/or diastolic blood pressure > 100 mmHg, acute myocardial infarction occurred within 6 months before enrollment; 6. Pregnant or lactating or planning to get pregnant within 1 year; 7. Allergic to contrast agents used in ultrasound, CT or MRI; 8. for general anesthesia; 9. The patient has participated in any clinical trial of drugs or medical devices within 3 months before this study; 10. History of other malignant tumors, spontaneous tumor rupture, severe comorbidities, acute or active infectious diseases, pregnancy or lactation within the past 5 years; 11. Undergoing any other experimental drugs or experimental medical devices; 12. Unable or refusing to follow the rules, participating in other clinical trials, refusing to provide informed consent, and the investigator believes that the patient has other conditions that make them unsuitable for participating in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete ablation rate within 30 days after surgery ; | — |
Secondary
| Measure | Time frame |
|---|---|
| 1-year postoperative local recurrence rate;Patient survival rate (Overall Survival, OS);Disease-free survival (DFS);Adverse event incidence rate; | — |
Countries
China
Contacts
Public ContactBiao Yang
West China Hospital of Sichuan University
Outcome results
None listed